Beyond Air (NASDAQ:XAIR – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 target price on the stock.
Other equities research analysts have also issued research reports about the company. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Beyond Air in a research note on Monday, December 22nd. Rodman & Renshaw initiated coverage on shares of Beyond Air in a research note on Tuesday, January 20th. They set a “buy” rating on the stock. Finally, Wall Street Zen upgraded Beyond Air to a “sell” rating in a report on Saturday. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.00.
View Our Latest Analysis on XAIR
Beyond Air Stock Performance
Beyond Air (NASDAQ:XAIR – Get Free Report) last released its quarterly earnings results on Friday, February 13th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.31). Beyond Air had a negative return on equity of 268.82% and a negative net margin of 447.75%.The company had revenue of $2.19 million for the quarter, compared to analysts’ expectations of $2.15 million. On average, analysts forecast that Beyond Air will post -0.79 EPS for the current year.
Institutional Investors Weigh In On Beyond Air
A number of institutional investors have recently made changes to their positions in XAIR. Geode Capital Management LLC lifted its position in shares of Beyond Air by 1.5% in the 2nd quarter. Geode Capital Management LLC now owns 838,319 shares of the company’s stock worth $144,000 after buying an additional 12,598 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in Beyond Air by 26.4% in the second quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock worth $29,000 after acquiring an additional 34,000 shares during the last quarter. Virtu Financial LLC acquired a new position in Beyond Air in the third quarter valued at approximately $48,000. Alyeska Investment Group L.P. bought a new position in shares of Beyond Air during the third quarter valued at approximately $1,753,000. Finally, Alpine Global Management LLC acquired a new stake in shares of Beyond Air during the 3rd quarter worth approximately $25,000. 31.50% of the stock is currently owned by institutional investors.
About Beyond Air
Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.
The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.
Featured Stories
- Five stocks we like better than Beyond Air
- Why this rare resource setup is catching early attention
- My Epstein Story
- Read this or regret it forever
- Buy this Gold Stock Before May 15th, 2026
- The Market Just Split in Two (URGENT)
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.
